Shots:
- Harbour BioMed has entered into a multi-year, global strategic collaboration & license agreement with BMS to discover & develop next-generation multi-specific antibodies leveraging the Harbour Mice platform
- As per the deal, Harbour BioMed & BMS will jointly identify & advance multi-specific antibody programs, with Harbour eligible for $90M in total payments, ~$1.03B in development & commercial milestones, plus tiered royalties if BMS elects to advance all programs
- Harbour Mice is a proprietary antibody platform that produces fully human monoclonal antibodies in both H2L2 (two heavy, two light chains) & heavy chain-only (HCAb) formats
Ref: PR Newswire | Image: Harbour BioMed & BMS | Press Release
Related News: BMS Reports the US FDA Approval of Breyanzi for R/R Marginal Zone Lymphoma (MZL)
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
